Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
Study Summary
This trialtests a new drug to find the safest dose for cancer patients.
Eligible Conditions
- Advanced Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Dose limiting toxicities (DLTs)
Secondary outcome measures
The pharmacokinetics of STP1002
Treatment-emergent adverse events (TEAEs)
Trial Design
1Treatment groups
Experimental Treatment
Group I: STP1002Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STP1002
2020
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
ST Pharm Co., Ltd.Lead Sponsor
1 Previous Clinical Trials
36 Total Patients Enrolled
KCRN Research, LLCIndustry Sponsor
8 Previous Clinical Trials
417 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are able to swallow pills or capsules.You have tumors that have spread to your brain, you have uncontrolled seizures, or you have an ongoing neurological condition.You have a serious heart condition.You are expected to live for at least 3 more months.You are currently receiving any other cancer treatment.
Research Study Groups:
This trial has the following groups:- Group 1: STP1002
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger